✦ LIBER ✦

Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without down syndrome

✍ Scribed by Mark D. Brissette; Bertrand J. Duval-Arnould; Bruce G. Gordon; Dr. James D. Cotelingam

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 677 KB
Volume: 47
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830470413

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute nonlymphocytic leukemia after tran

Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with down syndrome

✍ Barnett, P. L. J. ;Clark, A. C. L. ;Garson, A. C. M. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

## Abstract An infant with Down syndrome (DS) and RH isoimmunization developed transient myeloproliferative disorder (TMD) during the neonatal period. At 16 months she presented with acute nonlymphocytic leukemia (ANLL). Cytogenetic studies during TMD showed trisomy 21 only but new abnormalities em

“Leukemic” pattern of in vitro growth in

“Leukemic” pattern of in vitro growth in a patient with Down syndrome and transient myeloproliferative disorder

✍ Professor Barry Mendelow; Selma Krawitz; Richard Cohn; Renée Bernstein 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 2 views

Karyotype evolution in a patient with do

Karyotype evolution in a patient with down syndrome and acute leukemia following a congenital leukemoid reaction

✍ Sawyer, J. R. ;Roloson, G. J. ;Head, D. R. ;Becton, D. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB

## Abstract We report the serial cytogenetic study of a patient with Down syndrome who experienced a congenital leukemoid reaction, underwent a spontaneous remission within four months, and subsequently developed acute myeloid leukemia at 16 months. A blood chromosome study to rule out Down syndrom

The myeloproliferative reaction in a chi

The myeloproliferative reaction in a child with down syndrome: Cytological and chromosomal evidence for a transient leukemia

✍ Kenneth H. Lazarus; Nyla A. Heerema; Catherine G. Palmer; Robert L. Baehner 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 596 KB

Infants with Down's syndrome. Use of cyt

Infants with Down's syndrome. Use of cytogenetic studies and In Vitro colony assay for granulocyte progenitor to distinguish acute nonlymphocytic leukemia from a transient myeloproliferative disorder

✍ Pedro A. De Alarcon; Shivanand Patil; Jack Golberg; Judith B. Allen; Susan Shaw 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 694 KB

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated